Search company, investor...

Founded Year

1984

Stage

IPO | IPO

Total Raised

$2.2M

Date of IPO

7/1/1991

Market Cap

47.24B

Stock Price

555.54

About IDEXX Laboratories

IDEXX Laboratories is a company focused on pet healthcare innovation, operating within the veterinary and animal health industry. The company offers a range of diagnostic and information technology-based products and services, including in-clinic diagnostic tests, reference laboratory and telemedicine consultation services, and practice management software. These products and services are primarily sold to the veterinary industry. It was founded in 1984 and is based in Westbrook, Maine.

Headquarters Location

One IDEXX Drive

Westbrook, Maine, 04092,

United States

207-556-0300

Loading...

Loading...

IDEXX Laboratories Patents

IDEXX Laboratories has filed 210 patents.

The 3 most popular patent topics include:

  • blood tests
  • analytical chemistry
  • molecular biology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/14/2021

2/20/2024

Fatty acids, Analytical chemistry, Microarrays, Molecular biology, Water pollution

Grant

Application Date

9/14/2021

Grant Date

2/20/2024

Title

Related Topics

Fatty acids, Analytical chemistry, Microarrays, Molecular biology, Water pollution

Status

Grant

Latest IDEXX Laboratories News

IDEXX Laboratories to Present at Two Upcoming Institutional Investor Conferences

Feb 20, 2024

IDEXX Laboratories to Present at Two Upcoming Institutional Investor Conferences February 20, 2024 at 02:01 pm EST Share IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, will participate in two upcoming conferences: Thursday, February 29, 10:50 am – 11:30 am EST – Brian McKeon, Executive Vice President and Chief Financial Officer, and Tina Hunt, PhD, Executive Vice President, Strategy, Sector Development and Global Operations, will participate in a fireside chat at the BofA Securities Animal Health Virtual Summit. Monday, March 4, 11:00 am – 11:30 am EST – Jay Mazelsky, President and Chief Executive Officer, will present at the 45th Annual Raymond James Institutional Investors Conference. Individuals can access the live audio webcasts of the presentations through links on the IDEXX website, www.idexx.com/investors. An archived edition of the presentations will be available via the same link. About IDEXX Laboratories, Inc. IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help ensure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500® Index. Headquartered in Maine, IDEXX employs nearly 11,000 people and offers solutions and products to customers in more than 175 countries and territories. For more information about IDEXX, visit www.idexx.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20240220666980/en/ Share

IDEXX Laboratories Frequently Asked Questions (FAQ)

  • When was IDEXX Laboratories founded?

    IDEXX Laboratories was founded in 1984.

  • Where is IDEXX Laboratories's headquarters?

    IDEXX Laboratories's headquarters is located at One IDEXX Drive, Westbrook.

  • What is IDEXX Laboratories's latest funding round?

    IDEXX Laboratories's latest funding round is IPO.

  • How much did IDEXX Laboratories raise?

    IDEXX Laboratories raised a total of $2.2M.

  • Who are the investors of IDEXX Laboratories?

    Investors of IDEXX Laboratories include Flagship Ventures, North Atlantic Capital, Venrock and Maine Capital.

  • Who are IDEXX Laboratories's competitors?

    Competitors of IDEXX Laboratories include Hypercell Technologies, ANIWARE, Acumen Pharmaceuticals, Fujirebio, Panacea Pharmaceuticals and 7 more.

Loading...

Compare IDEXX Laboratories to Competitors

F
Fujirebio

Fujirebio is a company with over 50 years of expertise in the in vitro diagnostics industry, focusing on the development, manufacturing, and marketing of diagnostic testing solutions. The company offers a range of products including automated testing instruments, kits for manual or semi-automated testing, and software solutions for reading and interpretation, all designed to aid in the diagnosis of various diseases and conditions. Fujirebio primarily serves the healthcare industry, with a strong emphasis on clinical laboratories and research institutions. It was founded in 1985 and is based in Ghent, Belgium.

V
Vybion

Vybion is a biotechnology company focused on the development of Intrabodies for neurodegenerative diseases. The company's main offerings include therapeutic Intrabodies designed to modify disease progression by targeting and altering intracellular events such as protein aggregation and gene dysregulation. Vybion's products are primarily aimed at addressing unmet medical needs in the treatment of orphan diseases like Huntington's disease.

C
CellXplore

CellXplore is a new, biotechnology company engaged in the development of biomarker-based in vitro diagnostic assays for cancer, initially focusing on breast cancer. Although mammography is an effective screening test for early detection, there is a need for a simple, reliable and sensitive biomarker-based in vitro assay that can be used to stage and characterize breast cancer.nThe company was formed to commercialize groundbreaking discoveries demonstrating up-regulation of the ubiquitin-proteasome pathway in cancerous breast tissue, providing the capability for the noninvasive detection of breast cancer and the ability to monitor the efficacy of chemotherapeutic interventions.nCellXplore's platform technology is not restricted to breast cancer in vitro diagnostics alone, nor is it restricted to cancer diagnostics alone. Beyond cancer, CellXplore is already investigating whether similar blood sample biomarkers can be identified for the early diagnosis of several major debilitating diseases such as muscle wasting, Alzheimer's disease, Parkinson's disease and inflammatory diseases.

T
Targeson

Targeson is a biotechnology company that develops, manufactures, and markets ultrasound contrast agent technologies for pre-clinical molecular imaging in animal models. Targeson is also developing this technology for site-specific diagnosis and therapy in humans. The company has engineered a versatile microparticle platform that may be used as both a contrast agent and, in a slightly modified form, a drug or gene delivery agent. Targeson manufactures and sells the Targestarline of contrast agents for ultrasound-based molecular and functional imaging in animal models of disease. Targeson's agents can be readily targeted to the molecular signature of many diseases, and can be used to detect pathophysiology on the molecular level. The company's intellectual property aims to enable the agents to bind with high efficiency to the intended molecular targets. In addition, the company is investigating therapeutic technology for simultaneous imaging and delivery, which aims to enable the user to verify that the therapeutic compound has been delivered to the intended site.

A
ARCXIS

ARCXIS is a professional services company specializing in the residential construction market, offering a suite of inspection, engineering, and energy efficiency services. The company provides comprehensive solutions including residential inspections, energy assessments, and engineering services designed to optimize building processes and ensure code compliance. ARCXIS primarily serves the residential construction sector, delivering services that enhance building quality and efficiency. It was founded in 2004 and is based in Houston, Texas.

T
TOP (Transgenic Operative Products) srl

nnBy transferring to preclinical research the non-invasive modalities used for human diagnostics, TOP strives for an ethical use of animal models in full compliance with the 3Rs rule. With its alternative models, TOP intends to nullify animal suffering, Reduce animal use, Replace current in vivo methodologies and Refine biomedical research tools with the generation of more predictive models for the study of the molecular basis of human diseases and the effects of therapies.n

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.